<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="complications Steroids Antivirals (if steroid refractory) IC: anti-EBV CTLs antivirals" exact="Ganciclovir" post="Valganciclovir Valacyclovir Famiclovir Foscarent CMV IC Solid organ transplant"/>
 <result pre="Steroids Antivirals (if steroid refractory) IC: anti-EBV CTLs antivirals Ganciclovir" exact="Valganciclovir" post="Valacyclovir Famiclovir Foscarent CMV IC Solid organ transplant recipients"/>
 <result pre="Antivirals (if steroid refractory) IC: anti-EBV CTLs antivirals Ganciclovir Valganciclovir" exact="Valacyclovir" post="Famiclovir Foscarent CMV IC Solid organ transplant recipients Neonates"/>
 <result pre="end organ disease IC—antivirals ± IVIG Organ transplant recipients—prophylactic vs. preemptive treatment" exact="Ganciclovir" post="Valganciclovir Foscarnet Cidofovir CMV hyperimmune globulin Leflunomide HSV IC"/>
 <result pre="organ disease IC—antivirals ± IVIG Organ transplant recipients—prophylactic vs. preemptive treatment Ganciclovir" exact="Valganciclovir" post="Foscarnet Cidofovir CMV hyperimmune globulin Leflunomide HSV IC Pregnancy"/>
 <result pre="IC—antivirals ± IVIG Organ transplant recipients—prophylactic vs. preemptive treatment Ganciclovir Valganciclovir Foscarnet" exact="Cidofovir" post="CMV hyperimmune globulin Leflunomide HSV IC Pregnancy (third trimester)"/>
 <result pre="vs. preemptive treatment Ganciclovir Valganciclovir Foscarnet Cidofovir CMV hyperimmune globulin" exact="Leflunomide" post="HSV IC Pregnancy (third trimester) Neonates Leukopenia, thrombocytopenia, relatively"/>
 <result pre="at the margins of the foci of necrosis Early high-dose" exact="acyclovir" post="Acyclovir VZV Adults IC Liver transplant recipients Cutaneous rash"/>
 <result pre="and intranuclear inclusions with an inflammatory response) Early therapy with" exact="acyclovir" post="in severe disease or IC patients Acyclovir IC immunocompromised,"/>
 <result pre="be monitored closely for acute allograft rejection. Newer immunosuppressants, including" exact="mycophenolate mofetil" post="and sirolimus, appear to be associated with fewer post-transplant"/>
 <result pre="in the oropharynx but does not reduce viremia or symptoms." exact="Ganciclovir" post="was effective in the treatment of EBV hepatitis in"/>
 <result pre="have been described [52, 54]. Several cases were treated with" exact="ganciclovir" post="or with valganciclovir, some with fatal outcome despite therapy."/>
 <result pre="treatment of CMV disease include ganciclovir, valganciclovir, foscarnet, and cidofovir." exact="Ganciclovir" post="is considered the antiviral agent of choice against CMV."/>
 <result pre="measurements of CMV in blood samples. Emerging strains resistant to" exact="ganciclovir" post="pose a therapeutic challenge for which foscarnet or cidofovir"/>
 <result pre="to ganciclovir pose a therapeutic challenge for which foscarnet or" exact="cidofovir" post="may become alternative antiviral agents [58]. Valganciclovir has recently"/>
 <result pre="which foscarnet or cidofovir may become alternative antiviral agents [58]." exact="Valganciclovir" post="has recently been evaluated among liver transplant recipients with"/>
 <result pre="evaluated among liver transplant recipients with CMV disease [1, 56]." exact="Ganciclovir" post="can lead to myelosuppression, central nervous system disorders, hepatotoxicity,"/>
 <result pre="reduced in liver transplant recipients who receive antiviral prophylaxis with" exact="valganciclovir" post="or oral ganciclovir for the first 3 months following"/>
 <result pre="transplant recipients who receive antiviral prophylaxis with valganciclovir or oral" exact="ganciclovir" post="for the first 3 months following liver transplantation. CMV"/>
 <result pre="infection to full-blown clinical disease [67]. Preemptive therapy with oral" exact="ganciclovir" post="or intravenous ganciclovir or valganciclovir resulted in reduction of"/>
 <result pre="clinical disease [67]. Preemptive therapy with oral ganciclovir or intravenous" exact="ganciclovir" post="or valganciclovir resulted in reduction of CMV disease by"/>
 <result pre="[67]. Preemptive therapy with oral ganciclovir or intravenous ganciclovir or" exact="valganciclovir" post="resulted in reduction of CMV disease by 70 %"/>
 <result pre="unlike antiviral prophylaxis, was not associated with late-onset CMV disease." exact="Valganciclovir" post="is currently the most commonly used drug for preemptive"/>
 <result pre="very rapid [66]. For antiviral prophylaxis, antiviral drugs such as" exact="ganciclovir" post="and valganciclovir are administered to patients at risk of"/>
 <result pre="[66]. For antiviral prophylaxis, antiviral drugs such as ganciclovir and" exact="valganciclovir" post="are administered to patients at risk of CMV disease"/>
 <result pre="40 % reduction in CMV infection [68]. The use of" exact="acyclovir" post="as anti-CMV prophylaxis after liver transplantation has been supplanted"/>
 <result pre="as anti-CMV prophylaxis after liver transplantation has been supplanted by" exact="ganciclovir" post="and valganciclovir because of their superior efficacy [71, 76,"/>
 <result pre="prophylaxis after liver transplantation has been supplanted by ganciclovir and" exact="valganciclovir" post="because of their superior efficacy [71, 76, 77]. Prophylactic"/>
 <result pre="antiviral treatment of CMV disease after liver transplantation is intravenous" exact="ganciclovir" post="along with a reduction in the degree of pharmacologic"/>
 <result pre="with a reduction in the degree of pharmacologic immunosuppression [78]." exact="Valganciclovir" post="is a possible oral treatment for mild to moderate"/>
 <result pre="disease, treatment options include foscarnet, cidofovir, CMV hyperimmune globulins, or" exact="leflunomide" post="[69]. Compartmentalized CMV disease refers to clinical syndromes wherein"/>
 <result pre="The treatment of choice in these patients is early high-dose" exact="acyclovir" post="[81, 82]. Recurrence was not observed, suggesting that disseminated"/>
 <result pre="indicated for end organ disease and includes foscarnet, ganciclovir, and" exact="cidofovir" post="[86]. Varicella Zoster Virus Primary varicella infection is usually"/>
 <result pre="inclusions with an inflammatory response [1]. Early administration of intravenous" exact="acyclovir" post="is critical in the setting of VZV hepatitis, especially"/>
 <result pre="No specific therapy for adenovirus hepatitis is currently available, and" exact="cidofovir" post="has been recently suggested as an optional treatment [1]."/>
 <result pre="infectionHerpesviridae20112110.1186/2042-4280-2-121429244 12.LevitskyVMasucciMGManipulation of immune responses by Epstein-Barr virusVirus Res200288718610.1016/S0168-1702(02)00121-112297328 13.KagoyaYHangaishiATakahashiTImaiYKurokawaMHigh-dose" exact="dexamethasone" post="therapy for severe thrombocytopenia and neutropenia induced by EBV"/>
 <result pre="in liver transplantation: a randomized trial comparing a combination of" exact="ganciclovir" post="and acyclovir to acyclovir. NIDDK Liver Transplantation DatabaseTransplantation199764667310.1097/00007890-199707150-000139233703 71.GaneESalibaFValdecasasGJO’GradyJPescovitzMDLymanSRobinsonCARandomised"/>
 <result pre="transplantation: a randomized trial comparing a combination of ganciclovir and" exact="acyclovir" post="to acyclovir. NIDDK Liver Transplantation DatabaseTransplantation199764667310.1097/00007890-199707150-000139233703 71.GaneESalibaFValdecasasGJO’GradyJPescovitzMDLymanSRobinsonCARandomised trial of"/>
 <result pre="Transplantation DatabaseTransplantation199764667310.1097/00007890-199707150-000139233703 71.GaneESalibaFValdecasasGJO’GradyJPescovitzMDLymanSRobinsonCARandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
 <result pre="the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral" exact="Ganciclovir" post="International Transplantation Study Group [corrected]Lancet199735017293310.1016/S0140-6736(97)05535-99413463 72.LautenschlagerICMV infection, diagnosis and"/>
 <result pre="organ transplant recipientsClin Infect Dis2002358667210.1086/34238512228824 77.PayaCHumarADominguezEWashburnKBlumbergEAlexanderBFreemanRet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
 <result pre="Infect Dis2002358667210.1086/34238512228824 77.PayaCHumarADominguezEWashburnKBlumbergEAlexanderBFreemanRet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
 <result pre="disease in solid organ transplant recipientsAm J Transplant200446112010.1111/j.1600-6143.2004.00382.x15023154 78.AsbergAHansenCNReubsaetLDetermination of" exact="ganciclovir" post="in different matrices from solid organ transplanted patients treated"/>
</results>
